Autologous Cell Therapy Market To Reach $18.23 Billion By 2030

Autologous Cell Therapy Market Growth & Trends

The global autologous cell therapy market size is expected to reach USD 18.23 billion by 2030, registering a CAGR of 22.01% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growing burden of diseases and disorders such as cancer, neurodegenerative disorders, cardiovascular disorders, autoimmune disorders, and orthopedics are the factors driving the demand for the market. Likewise, the reduced risk of autologous cell therapy rejection is one of the important factors for market growth as these therapies are developed from patient-derived cells and support the regeneration of the damaged tissues in the body.

During the COVID-19 pandemic, the market has witnessed various challenges where patients were restricted to stay at home due to safety concerns. Some factors that affected the market growth are manufacturing hurdles and reduced patient inflow in hospitals. However, post-COVID-19 the market has witnessed the demand for the market with FDA clearance and all of the new advances in treating a wide range of disease indications.

In April 2020, Hope Biosciences, a clinical-stage biotechnology company announced the FDA clearance for a phase II clinical trial evaluating the efficacy & safety of HB-adMSCs (Hope Bioscience’ autologous, adipose-derived mesenchymal stem cells), to offer immune support against COVID-19. In June 2020, Chiesi Group and Holostem Terapie Avanzate mentioned the agreement for the transfer of the business branch Holoclar. The Holoclar is an autologous stem cell therapy for patients with ocular surface burns. It aims to allow both companies to focus on the strategic objective and accelerate procedures access for rare diseases.

 Request a free sample copy or view report summary: Autologous Cell Therapy Market Report

Autologous Cell Therapy Market Report Highlights

• The non-stem cell therapies segment dominated the market in 2024 with a 97.41% share. This large share can be attributed to several factors, including the expanding CAR T-cell therapy research landscape and increasing clinical trials.

• The oncology segment dominated the market in 2024 with an 88.55% share. CAR T-cells targeting CD19 can help treat Acute Lymphocytic Leukemia (ALL) patients with high rates of full and long-term remission.

• The North America autologous cell therapy market accounted for 57.88% share in 2024. The market is highly competitive since most major players operate in this region, such as BrainStorm Cell Therapeutics and Bristol Myers Squibb.

• Asia Pacific's autologous cell therapy market is anticipated to grow significantly over the forecast period.

Autologous Cell Therapy Market Segmentation

Grand View Research has segmented global autologous cell therapy market report based on therapy type, therapeutic area, and region:

Autologous Cell Therapy Therapy Type Outlook (Revenue, USD Million, 2018 - 2030)

• Autologous Therapies

  • Stem Cell Therapies

    • BM, Blood, & Umbilical Cord-derived Stem Cells

    • Adipose-derived cells

    • Others

  • Non-Stem Cell Therapies

    • T-Cell Therapies

      • CAR T Cell Therapy

      • T Cell Receptor (TCR)-based

    • Others

Autologous Cell Therapy Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)

• Oncology

• Cardiovascular Disease (CVD)

• Musculoskeletal Disorders

• Dermatology

• Others

Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • Switzerland

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

• Rest of the World

List of Key Players of Autologous Cell Therapy Market

• Bluebird bio, Inc.

• Novartis

• Gilead Sciences, Inc. (Kite)

• Bristol-Myers Squibb Company

• Pharmicell Co., Ltd.

• Johnson & Johnson (Janssen Global Services, LLC.)

• JW Therapeutics

• Holostem S.r.l.

• Vertex Pharmaceuticals, Inc.

• Autolus therapeutics